Jonathan B. Hurov, et.al., Loss of the Par-1b/MARK2 polarity kinase leads to increased metabolic rate, decreased adiposity, and insulin hypersensitivity in vivo., Proceedings of the National Academy of Sciences of the United States of America, 2007, 104

http://rdf.ncbi.nlm.nih.gov/pubmed/17372192

Jonathan B. Hurov, et.al., Loss of the Par-1b/MARK2 polarity kinase leads to increased metabolic rate, decreased adiposity, and insulin hypersensitivity in vivo., Proceedings of the National Academy of Sciences of the United States of America, 2007, 104

pubmed

表現型アノテーション

http://purl.org/net/cito/citesAsAuthority

• improved glucose tolerance_Mark2<tm1Hpw>/Mark2<tm1Hpw>
  http://metadb.riken.jp/0005292I129X1SvJC57BL6Mark2tm1HpwMark2tm1HpwMark2tm1Hpw
• hypoglycemia_Mark2<tm1Hpw>/Mark2<tm1Hpw>
  http://metadb.riken.jp/0000189I129X1SvJC57BL6Mark2tm1HpwMark2tm1HpwMark2tm1Hpw
• decreased susceptibility to diet-induced obesity_Mark2<tm1Hpw>/Mark2<tm1Hpw>
  http://metadb.riken.jp/0005659I129X1SvJC57BL6Mark2tm1HpwMark2tm1HpwMark2tm1Hpw
• abnormal eating behavior_Mark2<tm1Hpw>/Mark2<tm1Hpw>
  http://metadb.riken.jp/0001431I129X1SvJC57BL6Mark2tm1HpwMark2tm1HpwMark2tm1Hpw
• decreased circulating leptin level_Mark2<tm1Hpw>/Mark2<tm1Hpw>
  http://metadb.riken.jp/0005668I129X1SvJC57BL6Mark2tm1HpwMark2tm1HpwMark2tm1Hpw
• decreased body weight_Mark2<tm1Hpw>/Mark2<+>
  http://metadb.riken.jp/0001262I129X1SvJC57BL6Mark2tm1HpwMark2Mark2Mark2tm1Hpw
• abnormal glucose homeostasis_Mark2<tm1Hpw>/Mark2<tm1Hpw>
  http://metadb.riken.jp/0002078I129X1SvJC57BL6Mark2tm1HpwMark2tm1HpwMark2tm1Hpw
• increased basal metabolism_Mark2<tm1Hpw>/Mark2<tm1Hpw>
  http://metadb.riken.jp/0008965I129X1SvJC57BL6Mark2tm1HpwMark2tm1HpwMark2tm1Hpw
• increased energy expenditure_Mark2<tm1Hpw>/Mark2<tm1Hpw>
  http://metadb.riken.jp/0004889I129X1SvJC57BL6Mark2tm1HpwMark2tm1HpwMark2tm1Hpw
• decreased body length_Mark2<tm1Hpw>/Mark2<tm1Hpw>
  http://metadb.riken.jp/0001258I129X1SvJC57BL6Mark2tm1HpwMark2tm1HpwMark2tm1Hpw
• decreased circulating insulin level_Mark2<tm1Hpw>/Mark2<tm1Hpw>
  http://metadb.riken.jp/0002727I129X1SvJC57BL6Mark2tm1HpwMark2tm1HpwMark2tm1Hpw
• decreased circulating insulin-like growth factor I level_Mark2<tm1Hpw>/Mark2<tm1Hpw>
  http://metadb.riken.jp/0004701I129X1SvJC57BL6Mark2tm1HpwMark2tm1HpwMark2tm1Hpw
• increased insulin sensitivity_Mark2<tm1Hpw>/Mark2<tm1Hpw>
  http://metadb.riken.jp/0002891I129X1SvJC57BL6Mark2tm1HpwMark2tm1HpwMark2tm1Hpw
• decreased body weight_Mark2<tm1Hpw>/Mark2<tm1Hpw>
  http://metadb.riken.jp/0001262I129X1SvJC57BL6Mark2tm1HpwMark2tm1HpwMark2tm1Hpw
• decreased embryo weight_Mark2<tm1Hpw>/Mark2<tm1Hpw>
  http://metadb.riken.jp/0009429I129X1SvJC57BL6Mark2tm1HpwMark2tm1HpwMark2tm1Hpw
• increased adipocyte glucose uptake_Mark2<tm1Hpw>/Mark2<tm1Hpw>
  http://metadb.riken.jp/0030016I129X1SvJC57BL6Mark2tm1HpwMark2tm1HpwMark2tm1Hpw
• decreased circulating cholesterol level_Mark2<tm1Hpw>/Mark2<tm1Hpw>
  http://metadb.riken.jp/0005179I129X1SvJC57BL6Mark2tm1HpwMark2tm1HpwMark2tm1Hpw
• decreased circulating triglyceride level_Mark2<tm1Hpw>/Mark2<tm1Hpw>
  http://metadb.riken.jp/0002644I129X1SvJC57BL6Mark2tm1HpwMark2tm1HpwMark2tm1Hpw
• decreased susceptibility to hepatic steatosis_Mark2<tm1Hpw>/Mark2<tm1Hpw>
  http://metadb.riken.jp/0002310I129X1SvJC57BL6Mark2tm1HpwMark2tm1HpwMark2tm1Hpw
• decreased percent body fat/body weight_Mark2<tm1Hpw>/Mark2<tm1Hpw>
  http://metadb.riken.jp/0005459I129X1SvJC57BL6Mark2tm1HpwMark2tm1HpwMark2tm1Hpw
• decreased white adipose tissue amount_Mark2<tm1Hpw>/Mark2<tm1Hpw>
  http://metadb.riken.jp/0001783I129X1SvJC57BL6Mark2tm1HpwMark2tm1HpwMark2tm1Hpw
• decreased brown adipose tissue amount_Mark2<tm1Hpw>/Mark2<tm1Hpw>
  http://metadb.riken.jp/0001780I129X1SvJC57BL6Mark2tm1HpwMark2tm1HpwMark2tm1Hpw